Market Intelligence, Clinical Progress, and High-Purity Reagents for Extra-Oral Therapeutic Development (Respiratory, Metabolic, and Innate Immunity).
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TAS2R38 drug discovery. As a complex multi-pass membrane GPCR, cell-based assays are the only way to preserve conformation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | TAS2R38 Lentivirus Premade Particles (PAV/AVI variants). Full-length ORF for stable cell lines. High titer (>1x10^8 TU/mL), Endotoxin <10 EU/mL, Sequence Verified. | View TAS2R38 Products |
| Antigen | TAS2R38 AVI/PAV Variant Membrane Preparations. HEK293 expressed, >95% purity, Sequence Verified, Endotoxin <1 EU/µg. For haplotype selectivity assays. | View TAS2R38 Products |
| Positive Control | Anti-TAS2R38 Reference Antibody (Polyclonal or Recombinant). Raised against N-terminal extracellular domain. Suitable for Flow Cytometry and IHC. | View TAS2R38 Products |
| Validator | TAS2R38 siRNA Set (3 unique sequences). For knockdown verification in calcium flux assays. HPLC purified, Sequence Verified. | View TAS2R38 Products |
| Related Target: TAS2R14 | Broadly tuned airway chemosensory bitter receptor; essential for subfamily selectivity counter-screens. | View TAS2R14 Products |
| Related Target: TAS2R19 | Heterodimerization partner in bitter taste signaling. Critical for selectivity screening. | View TAS2R19 Products |
| Related Target: GNAT3 (Gustducin α) | Downstream G-protein signaling partner; required for TAS2R38 signal transduction validation. | View GNAT3 Products |
| Related Target: TRPM5 | Crucial downstream ion channel for taste receptor signaling validation. | View TRPM5 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity for Functional Screens | Full-length Lentivirus transduction in HEK293; native glycosylation and multi-pass folding preserved. Co-expression with GNAT3 available for complete G-protein coupling. |
| Haplotype-Dependent Pharmacology (PAV vs AVI) | Matched PAV and AVI variant lentivirus and membrane preparations; sequence verified by Mass Spec. |
| Subfamily Off-Target Screening (TAS2R14/19/43) | Paralog panels available with strictly Sequence Verified identity for cross-reactivity testing. |
| False Positive Controls / Knockdown Validation | Validated siRNA set (3 unique sequences) for specific knockdown confirmation in signaling assays. |
| Difficult-to-Transfect Cell Lines (Airway Epithelial) | Lentivirus delivery optimized for primary and immortalized respiratory cells; puromycin selection marker included. |
| Cross-Species Translation (Mouse / Cyno) | Human, mouse, and cynomolgus ortholog lentivirus particles available for preclinical assay continuity. |
Live TAS2R38 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of TAS2R38 has expanded significantly beyond gustation into respiratory immunity and metabolic regulation. TAS2R38 is highly expressed in the upper respiratory tract where it detects bacterial quorum-sensing molecules (e.g., acyl-homoserine lactones), making it a prime target for chronic rhinosinusitis (CRS), asthma, and Pseudomonas aeruginosa clearance in cystic fibrosis. As first-generation bitter agonists (denatonium, quinine) reach Phase II for respiratory indications, the next wave of R&D is targeting inhalation-delivered small molecule agonists that stimulate nitric oxide production, enhance mucociliary clearance, and activate innate immune responses without systemic toxicity. Concurrently, haplotype-specific personalized therapies based on PAV/AVI polymorphism status are emerging, along with combination approaches leveraging CFTR modulators (e.g., Trikafta) for cystic fibrosis. In the metabolic domain, stimulation of gut bitter receptors can delay gastric emptying and promote GLP-1/CCK secretion, positioning TAS2R38 as a potential oral adjuvant for GLP-1-based therapies.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist (Respiratory) | Bayer, Novartis, Emerging Biotech / Academic Spin-offs | Chronic Rhinosinusitis, Asthma, CF | Calcium Flux Assay (Need stable lentivirus cell lines with PAV/AVI variants) |
| Selective Modulator (Haplotype-targeted) | Biotech startups (e.g., Arivale pipeline) | Respiratory Infections, CF | Off-target Panel (Need TAS2R19/TAS2R43 for selectivity screening) |
| Topical / Nasal Spray | Mid-size Pharma | Upper Respiratory Infections | Polymorphism Screening (Need PAV/AVI specific ORFs) |
| Metabolic Modulator (Gut) | Nutraceutical / GI Pharma | Obesity, Metabolic Syndrome | Receptor Internalization & Calcium Flux (Need precise antibodies and stable cell lines) |
| Antibody-based (emerging) | Academic consortia | Receptor Trafficking Studies | Extracellular Domain Detection (Need N-terminal specific antibodies) |